Public Meeting on Patient-Focused Drug Development for Sarcopenia; Request for Comments; Correction

---
identifier: "/us/fr/2017-05247"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Public Meeting on Patient-Focused Drug Development for Sarcopenia; Request for Comments; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2017-05247"
section_name: "Public Meeting on Patient-Focused Drug Development for Sarcopenia; Request for Comments; Correction"
positive_law: false
currency: "2017-03-16"
last_updated: "2017-03-16"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2017-05247"
document_type: "notice"
publication_date: "2017-03-16"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "82 FR 14002"
fr_volume: 82
docket_ids:
  - "Docket No. FDA-N-2016-4198"
fr_action: "Notice; correction."
---


#  Public Meeting on Patient-Focused Drug Development for Sarcopenia; Request for Comments; Correction

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice; correction.

**SUMMARY:**

The Food and Drug Administration is correcting a notice entitled “Public Meeting on Patient-Focused Drug Development for Sarcopenia” that appeared in the *Federal Register* of December 14, 2016 (81 FR 90361). The document announced a public meeting and an opportunity for public comment on Patient-Focused Drug Development for Sarcopenia. The location of the meeting has changed and this document provides the updated meeting location.

**FOR FURTHER INFORMATION CONTACT:**

Meghana Chalasani, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 1146, Silver Spring, MD 20993-0002, 240-402-6525, FAX: 301-847-8443, *[email protected].*

In the *Federal Register* of Wednesday, December 14, 2016, in FR Doc. 2016-29998, the following correction is made:

1. On page 90361, in the second column, in the first sentence of the *ADDRESSES* section, “FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room, (Rm. 1503), Silver Spring, MD 20993-0002.” is corrected to read “Tommy Douglas Conference Center, 10000 New Hampshire Ave., Silver Spring, MD 20903.”

Dated: March 13, 2017.

Leslie Kux,

Associate Commissioner for Policy.